Betta Pharmaceuticals
Hangzhou · Founded 2003
About Betta Pharmaceuticals
Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to the R&D and manufacturing of National Class A new medicines with independent IPR. Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders in 2003, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to diseases severely influencing human health, e.g. malignant tumors, diabetes, and cardio-cerebrovascular disease. Its headquarters is located at Yuhang Economic and Technological Development Zone, Hangzhou City, with a pharmaceutical R&D center established in Beijing and Hangzhou respectively. At present, it boasts a team of nearly 1,000 employees, in which there are dozens of returned PhD holders with five of them included in The Recruitment Program of Global Experts of China. On Nov. 7th, 2016, Betta Pharmaceuticals was successfully listed in GEM of Shenzhen Stock Exchange. Betta has over 20 new drug development projects currently, among which its flagship product, Icotinib Hydrochloride (Conmana), has created several records: in Jul. 2012, it was involved in The International Annual Report on New Drug Research and Development, as the first targeted anti-cancer drug made in China; in Aug. 2013, Lancet Oncol, a world leading medical magazine, published a full text of China’s clinical research achievement of innovative drugs for the first time and commended that “Icotinib Hydrochloride has created the new era of China’s R&D of anti-cancer drugs”, according to the Editor’s Note; the compound and crystal form patents of Icotinib Hydrochloride won the Golden Prize of China Patent Award in 2012 and 2014 respectively; the R&D and industrialized achievement of Icotinib Hydrochloride won the First Prize of 2015 National Prize for Progress in Science and Technology, as the first time that this award was won by China’s chemical pharmaceutical industry and Zhejiang enterprise; in 2016, Icotinib Hydrochloride (Conmana) won the highest award of China’s industrial area, China Grand Award for Industry. The Company possesses over 100 authorized patents with other hundreds of patents applied in process; sets 4 technical standards, in which the standard for Icotinib Hydrochloride crude drugs and tablets has turned into national standard; won national special award of Key Formulation of New Drugs for several times and was involved in MOST National High-tech R&D Program (863 Program), China Torch Program and National Strategic Innovative Product. Independent R&D, strategic cooperation and marketing are the three driving factors promoting the better and faster development of Betta, laying a solid foundation for the realization of its strategic vision of “turning into a transnational pharmaceutical enterprise headquartered in China”. Innovation is of no bounds. Betta Pharmaceuticals will continue to carry forward its development concept as pioneering innovation to the benefit of the public, devote itself to innovation for the public and technology development benefiting the public by means of development of new medicines, to provide Chinese residents with more affordable medicines of good quality.
Company Facts
- Founded: 2003
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $499.7M
- Funding stage: IPO
- Last round: Series B (Jan 2013)
- Ticker: szse:300558
- Website: en.bettapharma.com
- Phone: 0571-86130357
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/betta-pharmaceuticals-40086 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.